临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 41733-55-5

Furosemide sodium

中文名称:5-(氨基磺酰基)-4-氯-2-(呋喃-2-基甲基)邻氨基苯甲酸钠
CAS号:41733-55-5
分子式: C12H10ClN2NaO5S 分子量: 352.73
产品形式: Sodium
研发状态: Recruiting
研发用途: Amyloidosis; Amyloidosis Cardiac; ATTR Amyloidosis Wild Type
研究机构: Paolo Milani; IRCCS Policlinico S. Matteo
研发日期: January 26 2024
研发阶段: --
Furosemide (Frusemide) sodium is a potent and orally active inhibitor of Na-K-Cl cotransporter (NKCC). Furosemide sodium is a subtype-selective antagonist of gamma-aminobutyric acid type A (GABAA) receptor.

CAS: 41621-49-2

Ciclopirox ethanolamine

中文名称:环吡酮胺
CAS号:41621-49-2
分子式: C12H17NO2.C2H7NO 分子量: 268.35
产品形式: Ethanolamine
研发状态: Completed
研发用途: Hematologic Malignancy; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Hodgkin''s Disease
研究机构: University Health Network Toronto; The Leukemia and Lymphoma Society
研发日期: Oct-09
研发阶段: Phase 1
Ciclopirox ethanolamine (Ciclopirox olamine, HOE 296,Ciclopiroxolamine) is a broad-spectrum antifungal agent working as an iron chelator.

CAS: 415903-37-6

Grapiprant (CJ-023,423)

CAS号:415903-37-6
分子式: C26H29N5O3S 分子量: 491.61
产品形式: Free Base
研发状态: Terminated
研发用途: Non-small Cell Lung Cancer Adenocarcinoma
研究机构: Arrys Therapeutics; Merck Sharp & Dohme LLC
研发日期: January 8 2019
研发阶段: Phase 1 : Phase 2
Grapiprant (CJ-023,423, AT-001, AAT-007, RQ-00000007, CJ-23423) is a novel selective EP4 Prostaglandin Receptor inhibitor with Ki of 20 nM and 13 nM for rat EP4 receptor and human EP4 receptor, respectively.

CAS: 41468-25-1

Pyridoxal 5-phosphate monohydrate

中文名称:5-磷酸吡哆醛
CAS号:41468-25-1
分子式: C8H10NO6P.H2O 分子量: 265.16
产品形式: hydrate
研发状态: Completed
研发用途: Pyridoxine Dependant Epilepsy
研究机构: Vitaflo International Ltd; Radboud University Medical Center; Great Ormond Street Hospital for Children NHS Foundation Trust
研发日期: June 1 2021
研发阶段: Not Applicable
Pyridoxal 5-phosphate monohydrate is an active vitamin B6 metabolite, which is a cofactor in many reactions of amino acid metabolism.

CAS: 41294-56-8

Alfacalcidol

中文名称:阿法骨化醇
CAS号:41294-56-8
分子式: C27H44O2 分子量: 400.64
产品形式: free base
研发状态: Completed
研发用途: Cardiac Valve Replacement Complication
研究机构: Cairo University
研发日期: April 1 2017
研发阶段: Phase 4
Alfacalcidol (1-hydroxycholecalciferol) is a non-selective VDR activator medication.

CAS: 41100-52-1

Memantine HCl

中文名称:盐酸美金刚
CAS号:41100-52-1
分子式: C12H21N.HCl 分子量: 215.76
产品形式: Hydrochloride
研发状态: Recruiting
研发用途: Neurocognitive Dysfunction
研究机构: Tata Memorial Centre
研发日期: February 22 2024
研发阶段: Phase 3
Memantine HCl is an antagonist of NMDAR. It is also a CYP2B6 and CYP2D6 inhibitor for recombinant CYP2B6 and CYP2D6 with IC50 of 1.12 μM and 242.4 μM, Ki of 0.51 μM and 84.4 μM, respectively.